

MEETING UNDER SECTION 249D OF CORPORATIONS ACT WITHDRAWN

11 January 2018

Anteo Diagnostics Ltd (ASX: ADO) ("**Anteo**" or "**Company**") advises that First Cape Management Pty. Limited and Austcorp No. 190 Pty. Limited ("FCM") have withdrawn their notice in accordance with Section 249D of the Corporations Act 2001 (Cth) that the Company received on the 21st December 2017.

The withdrawal follows discussions with FCM and other shareholders, who desired a Board renewal process that has the backing of shareholders and can provide the stability, direction and energy needed by Anteo. Our new CEO, Dr Stefan Enderling, will then have the Board support and access he needs to focus on creating shareholder value through effective commercialisation of the Anteo technology.

The search for an Independent Chairman, that meets the gap in skill sets previously identified in the Company Board review process conducted last year, will commence immediately. The Company is committed to an appointment that is supported by all Board members and the Company's CEO.

As part of the Board renewal process and to facilitate an orderly transition Mr Rolf Sickman will be retiring on 31 March, 2018 and Dr John Hurrell by 30 June, 2018.

Dr John Hurrell commented on behalf of the Board that, "We as directors are here to serve and act in the best interests of shareholders. Discussions with various stakeholders were held to better understand their concerns on a number of issues, particularly the desire to have an Australian domiciled Board that can effectively embody the interests of shareholders. All of the parties involved had the best interests of shareholders in mind and we are pleased to be able to agree an outcome that will help set up a strong future for Anteo."

Dr Stefan Enderling said "I look forward to the future of Anteo and working with all stakeholders to realise the potential of the Company's technology. This potential will be realised through the commercialisation of a range of business opportunities in multibillion dollar markets. The commercialisation of these business opportunities will provide the foundation for the sustainable future growth of the Company. Our Board renewal process will also underpin our future growth trajectory and I welcome the appointment of a new Chairman that can continue to support the work commenced by the existing Board."

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit www.anteotech.com